News summaryThe Motley FoolNov 2, 2026, 12:22 PM
UBS Just Initiated Coverage of Viking Therapeutics With a Buy Rating and a $94 Target. Here's the Bull Case.
UBS initiated coverage of Viking Therapeutics on Oct. 14 with a Buy rating and a 12-month price target of $94. [[fact-xgpa6ds7y]] In Viking’s phase 2 Venture trial, its injectable treatment produced average weight reductions of up to 14.7% after 13 weekly doses. [[fact-upk944nnj]] Earlier phase 2 results showed that patients taking oral VK2735 lost up to 12.2% of their body weight after 13 weeks. [[fact-x1r98iyw5]] Viking announced on Oct. 14 that it had initiated the Phase 3 Sunrise clinical program for oral VK2735. [[fact-kv066hacc]]